CRISPR Therapeutics AG $CRSP Stock Sold by Sumitomo Mitsui Trust Group Inc.

Sumitomo Mitsui Trust Group Inc. lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 15.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,453,713 shares of the company’s stock after selling 267,021 shares during the period. Sumitomo Mitsui Trust Group Inc. owned 1.50% of CRISPR Therapeutics worth $80,419,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently bought and sold shares of CRSP. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of CRISPR Therapeutics during the third quarter worth approximately $273,000. SFE Investment Counsel raised its position in CRISPR Therapeutics by 5,892.2% in the 3rd quarter. SFE Investment Counsel now owns 19,404 shares of the company’s stock valued at $1,073,000 after purchasing an additional 19,739 shares during the last quarter. Profund Advisors LLC raised its position in CRISPR Therapeutics by 42.9% in the 3rd quarter. Profund Advisors LLC now owns 41,562 shares of the company’s stock valued at $2,299,000 after purchasing an additional 12,479 shares during the last quarter. Choreo LLC boosted its stake in CRISPR Therapeutics by 3.4% during the 3rd quarter. Choreo LLC now owns 7,539 shares of the company’s stock worth $417,000 after purchasing an additional 247 shares during the period. Finally, Interchange Capital Partners LLC boosted its stake in CRISPR Therapeutics by 6.0% during the 3rd quarter. Interchange Capital Partners LLC now owns 4,766 shares of the company’s stock worth $264,000 after purchasing an additional 268 shares during the period. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Stock Performance

NASDAQ:CRSP opened at $49.99 on Wednesday. The firm’s fifty day moving average price is $53.86 and its 200 day moving average price is $52.85. CRISPR Therapeutics AG has a 1-year low of $44.12 and a 1-year high of $63.45. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The firm has a market cap of $4.83 billion, a price-to-earnings ratio of -10.55 and a beta of 1.92.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, November 2nd. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.06) by ($0.09). CRISPR Therapeutics had a negative net margin of 1,812.07% and a negative return on equity of 24.96%. The firm had revenue of $12.67 million during the quarter, compared to analyst estimates of $14.75 million. CRISPR Therapeutics’s quarterly revenue was up 1311.1% on a year-over-year basis. On average, sell-side analysts expect that CRISPR Therapeutics AG will post -4.44 EPS for the current year.

Insider Activity

In related news, Director Simeon George sold 14,514 shares of the stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $49.63, for a total transaction of $720,329.82. Following the completion of the transaction, the director directly owned 15,486 shares of the company’s stock, valued at $768,570.18. This represents a 48.38% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Samarth Kulkarni sold 47,837 shares of the firm’s stock in a transaction dated Monday, October 19th. The shares were sold at an average price of $49.78, for a total transaction of $2,381,325.86. Following the completion of the sale, the chief executive officer owned 311,899 shares of the company’s stock, valued at approximately $15,526,332.22. The trade was a 13.30% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last three months, insiders have sold 93,558 shares of company stock valued at $4,881,663. 5.20% of the stock is owned by insiders.

Analyst Ratings Changes

CRSP has been the topic of several research reports. Citizens Jmp reissued a “market outperform” rating and set a $80.00 price objective on shares of CRISPR Therapeutics in a research report on Monday, August 31st. Citigroup reissued a “market outperform” rating on shares of CRISPR Therapeutics in a report on Tuesday. UBS Group began coverage on CRISPR Therapeutics in a report on Thursday, October 15th. They set a “neutral” rating and a $52.00 price target on the stock. Needham & Company LLC restated a “buy” rating and issued a $82.00 price target on shares of CRISPR Therapeutics in a research report on Tuesday. Finally, The Goldman Sachs Group reaffirmed a “neutral” rating and set a $55.00 price objective on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $65.75.

More CRISPR Therapeutics News

Here are the key news stories impacting CRISPR Therapeutics this week:

• Positive Sentiment: Casgevy continued to gain traction: the company reported $99 million in third-quarter Casgevy revenue, up 30% from the prior quarter and nearly sixfold year over year. The treatment also received pediatric approvals in the U.K., UAE and Bahrain, expanding its potential patient reach. Company Q3 business update
• Positive Sentiment: CRISPR Therapeutics said the FDA granted RMAT designations to CTX310, with early clinical data expected at an upcoming medical meeting. The company also reported progress in other programs, including completed enrollment in a Phase 2 CTX611 trial. These developments provide potential future catalysts, though clinical outcomes remain uncertain. Company Q3 business update
• Positive Sentiment: Needham reaffirmed its “Buy” rating and set an $82 price target, signaling analyst confidence in potential upside. Needham rating
• Neutral Sentiment: The company appointed Siva Sakhamuri as Chief Technical Officer. His manufacturing and technical-operations experience could support development and commercialization, but the appointment’s financial impact is not yet clear. CTO appointment
• Negative Sentiment: CRISPR Therapeutics reported a third-quarter loss of $1.15 per share, wider than the $1.06 loss analysts expected. Reported revenue of $12.67 million also missed estimates of about $14.75 million, despite the sharp year-over-year increase. The earnings shortfall may temper optimism around Casgevy’s growth. Q3 results coverage

CRISPR Therapeutics Company Profile

CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing transformative gene-based medicines using CRISPR/Cas9 gene-editing technology. The company’s research programs are designed to address genetic diseases by precisely modifying DNA in cells, with applications across hematology, immunology, oncology, regenerative medicine and cardiovascular disease.

Its lead commercial product is CASGEVY, an autologous cell therapy developed in collaboration with Vertex Pharmaceuticals.